11/20/2026 | Press release | Distributed by Public on 11/20/2026 03:59
Today's big story: Will 2027 Be A 2022 Repeat For Stocks?
Jazz Pharmaceuticals (JAZZ) produced $1.41 billion of free cash flow over the past twelve months. That equals 9.2% of its market value, against 4.4% for the median S&P 500 company. A yield that high marks one of two things: a business on sale, or one the market expects to shrink. Jazz also owes $5.65 billion, so not all of that cash is the owners' to keep. So what does that cash give you as an owner?
What Does Jazz's Cash Yield Give You?
As a shareholder, you own a slice of the free cash Jazz produces, whether or not it is paid out. That works the same way as your slice of its profit: cash that stays in the company still belongs to its owners. When the market recognizes that cash, the share price tends to follow, and more so when the cash is growing. That is why a yield about twice the median company's deserves a look.
Jazz's debt minus its cash, known as net debt, was $2.79 billion at the end of September 2026, equaling 18.2% of its market value. Measured against the company's whole value, debt included, Jazz's free cash flow yield is 7.8%.
How Jazz Makes Its Cash
Jazz focuses on drugs for rare diseases, and each sale costs it little to make. Its gross margin was 89.1% over the past twelve months. Sales of its sleep drug, Xywav, grew 12% to $483 million in the third quarter of 2026.
Jazz Pharmaceuticals' sleep drug Xywav alone brought in $483 million in the third quarter of 2026. If Jazz is a big part of your savings, your money is riding on a few drugs keeping their sales. Our partner advisory firm will take your question on a free 30-minute call, by phone or video, with no obligation. Book a free call.
Jazz also keeps most of its operating cash after capital spending. It put 16.5% of its cash from operations into capital spending over the past twelve months. Its free cash flow came to 30.0% of revenue.
That cash has grown. Jazz's free cash flow over the past twelve months was up from $1.24 billion a year earlier. Measured over twelve months at each of the last 13 quarter ends, its free cash flow stayed above zero, between $0.87 billion and $1.49 billion.
Jazz covers its interest with room to spare. Its operating income was 6.8 times its interest expense over the past twelve months. In the third quarter, Jazz issued $1.25 billion of convertible notes, debt that can turn into shares, management said. It also spent $820 million to buy Actio Biosciences, which adds an epilepsy drug in testing.
What Could Shrink Jazz's Cash?
New rivals for two of Jazz's drugs could cut into its sales. Management expects a competing drug, Imdelltra, to hurt Zepzelca in 2027 once it is approved in first-line maintenance, the setting behind Zepzelca's growth. Zepzelca sales rose 32% to $104 million in the third quarter. For Xywav, a new class of narcolepsy drugs could slow how quickly some new patients start treatment.
Buyers pay 9.0 times Jazz's cash from operations, against 15.0 for the S&P 500 taken as one company. The price appears to assume that some of this cash will not last. So far, the results lean the other way. Over the past twelve months, revenue rose 13.5% from a year earlier, and the operating margin reached 24.0%, up from 10.9% a year before. In November 2026, Jazz raised its 2026 revenue forecast to $4.81 billion at the midpoint, from $4.68 billion in August. So far, that looks more like a business on sale than one that is shrinking. The test comes in 2027, when the Zepzelca rival is expected.
Jazz is also building new sales. Its cancer drug Ziihera brought in $21 million in the third quarter, and management puts its peak sales potential at $3 billion to $5 billion.
Jazz has yet to show whether its cash keeps growing once those rivals arrive. Its interest cover is also measured over twelve months that mostly came before the third-quarter borrowing. Jazz is expected to report in February 2027. That report will show its free cash flow for all of 2026 and where its debt stands at year end.
Even Jazz's strong cash comes from a few drugs, and one rival's launch can knock a single stock down hard. Jazz pays no dividend, so none of its cash reaches you as income. Spreading your money across many companies that pay steady dividends can bring you regular income and gentler falls.
More Income. Smaller Drops.
Is your portfolio paying you enough? The Trefis Income Solution holds 50 dividend stocks yielding about 3x the S&P 500, each with at least 10 straight years of dividends. It lost less than the S&P 500 in all 9 big selloffs since 2018. Why not choose a better approach?
Spot an error or want more like this? Tell us in 10 seconds.